?
Can selective GluK1 antagonists provide neuroprotection in AD without disrupting baseline cognition?
active
open question
Created: 2026-04-25T20:28:56
By: backfill_open_questions
Quality:
50%
✓ SciDEX
ID: open_question-1653fb37-1f2e-4dde-821b-df
Open Question
open
Wiki: cell-types-kainate-receptor-neurons
Can selective GluK1 antagonists provide neuroprotection in AD without disrupting baseline cognition?
Importance Elo
1500
Field Rank
Rank #415 in cell
Tractability
0.50
Potential Impact
0.50
Evidence Summary
Extracted from wiki page cell-types-kainate-receptor-neurons
Secondary Market
No secondary market activity yet. Learn about share issuance →
Share Holder Leaderboard
No shares issued yet.
Evidence Bearing On This Question
No cross-references found yet. Evidence matching runs daily.
Pairwise Tournament History
No pairwise judgments recorded yet.
Derived Hypotheses And Proposals
No derived artifacts linked yet.
Related Entities
▸Metadata
| status | open |
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-26T03:28:56.067447'} |
| field_tag | cell |
| source_id | cell-types-kainate-receptor-neurons |
| sub_field | types-kainate-receptor-neurons |
| source_kind | wiki |
| question_hash | 8fc92dcc630497491fe4930628f8723d248a0e4b94c80a5f44c7c6e2c18eba96 |
| question_text | Can selective GluK1 antagonists provide neuroprotection in AD without disrupting baseline cognition? |
| importance_elo | 1500 |
| _schema_version | 1 |
| evidence_summary | Extracted from wiki page cell-types-kainate-receptor-neurons |
| tractability_score | 0.5 |
| potential_impact_score | 0.5 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.